肝脏巨噬细胞及其在肝损伤和修复中的作用

doi:10.12092/j.issn.1009-2501.2018.10.016

中国临床药理学与治疗学 ›› 2018, Vol. 23 ›› Issue (10): 1188-1195.doi: 10.12092/j.issn.1009-2501.2018.10.016

肝脏巨噬细胞及其在肝损伤和修复中的作用

王鹿¹，李丽萍¹，邢欣¹，徐登球¹，肖莉²，江振洲^1,3,4，张陆勇^1,5，孙丽新^1,3,4

¹ 中国药科大学，江苏省新药筛选重点实验室，南京 210009，江苏；²湖州师范学院生命科学学院，湖州 313000，浙江; ³中国药科大学药物质量与安全预警教育部重点实验室，南京 210009，江苏；⁴中国药科大学，江苏省药效研究与评价服务中心，南京 210009，江苏； ⁵广东药科大学药学院，新药筛选与药效学评价中心，广州 510006，广东

收稿日期:2018-03-30 修回日期:2018-04-19 出版日期:2018-10-26 发布日期:2018-10-25
通讯作者: 孙丽新，女，博士，硕士生导师，研究方向：中药毒理学。 Tel: 15195999925 E-mail: slxcpu@126.com
作者简介:王鹿，女，硕士研究生，研究方向：中药毒理学。 Tel: 15250961189 E-mail: wanglu1189@163.com
基金资助:
国家自然科学基金面上项目（81573690，81673684）；国家自然科学基金重大国际（地区）合作研究项目（81320108029）；2015年度中医药行业科研专项（201507004-002）；国家“十二五”重大新药创制专项（2015ZX09501004-002-004）

Hepatic macrophages in liver injury and repair

WANG Lu ¹, LI Liping ¹, XING Xin¹, XU Dengqiu¹, XIAO Li ², JIANG Zhenzhou ^1,3,4, ZHANG Luyong ^1,5, SUN Lixin ^1,3,4

¹Jiangsu Key Laboratory of Drug Screening, China Pharmaceutical University, Nanjing 210009, Jiangsu, China; ²College of Life Science, Huzhou University, Huzhou 313000, Zhejiang, China; ³ Key Laboratory of Drug Quality Control and Pharmacovigilance (China Pharmaceutical University), Ministry of Education, Nanjing 210009, Jiangsu, China; ⁴ Jiangsu Center for Pharmacodynamics Researchand Evaluation, China Pharmaceutical University, Nanjing 210009, Jiangsu, China; ⁵Center for Drug Screening and Pharmacodynamics Evaluation, School of Pharmacy, Guangdong Pharmaceutical University, Guangzhou 510006, Guangdong, China

Received:2018-03-30 Revised:2018-04-19 Online:2018-10-26 Published:2018-10-25

摘要/Abstract

摘要：

肝脏巨噬细胞在肝脏损伤和修复过程中具有重要调节作用，根据不同的来源和表型，肝脏巨噬细胞分别具有清除细菌病原体、呈递抗原、促进或者抑制肝脏炎症反应的能力，直接参与肝脏疾病的发生发展和损伤修复。本文就肝脏巨噬细胞的功能及其在肝脏损伤和修复中的调节作用进行综述，并总结治疗肝脏疾病的潜在巨噬细胞靶点。

关键词: 肝脏巨噬细胞, 肝损伤, 肝修复, 免疫

Abstract:

Hepatic macrophages play a critical role in the pathogenesis of liver injury and repair. It is noted that, based on the distinct origins and phenotypes, hepatic macrophages can clear bacterial pathogens, antigens, promote or inhibit the liver inflammation, which directly participate in the liver disease development and repair. This article reviews the functions and phenotypes of hepatic macrophages, and their roles in the different stages of liver injury and repair. Also, the potential macrophage-targeted therapies against liver diseases were also summarized.

Key words: hepatic macrophages, liver injury, liver repair, immunity

中图分类号:

王鹿，李丽萍，邢欣，徐登球，肖莉，江振洲，张陆勇，孙丽新. 肝脏巨噬细胞及其在肝损伤和修复中的作用[J]. 中国临床药理学与治疗学, 2018, 23(10): 1188-1195.

WANG Lu, LI Liping, XING Xin, XU Dengqiu, XIAO Li, JIANG Zhenzhou, ZHANG Luyong, SUN Lixin. Hepatic macrophages in liver injury and repair[J]. Chinese Journal of Clinical Pharmacology and Therapeutics, 2018, 23(10): 1188-1195.

参考文献

［1］Gordon S. Elie Metchnikoff, the man and the myth［J］. J Innate Immun, 2016, 8(3): 223-227.
［2］Lee CH, Choi EY. Macrophages and inflammation［J］. J Rhrum Dis, 2018, 25(1): 11-18.
［3］Tabas I, Bornfeldt KE. Macrophage phenotype and function in different stages of atherosclerosis［J］. Circ Res, 2016, 118(4): 653-667.
［4］Gomez Perdiguero E, Klapproth K, Schulz C, et al. Tissue-resident macrophages originate from yolk-sac-derived erythro-myeloid progenitors［J］. Nature, 2015, 518(7540): 547-551.
［5］夏园, 乔建林, 曾令宇. 组织固有巨噬细胞的研究进展［J］. 细胞与分子免疫学杂志, 2016, 32(7): 996-999.
［6］Hamidzadeh K, Christensen SM, Dalby E, et al. Macrophages and the recovery from acute and chronic inflammation［J］. Annu Rev Physiol, 2017, 79(1): 567-592.
［7］Mossanen JC, Krenkel O, Ergen C, et al. Chemokine (C-C motif) receptor 2-positive monocytes aggravate the early phase of acetaminophen induced acute liver injury［J］. Hepatology, 2016, 64(5): 1667-1682.
［8］Puengel T, Tacke F. Repair macrophages in acute liver failure［J］. Gut, 2017, 67(2): 202-203.
［9］白杨, 杨勇. 肝脏相关巨噬细胞起源及发育分化研究进展［J］. 药学研究, 2018, 37(1): 50-52.
［10］Gao B. Basic liver immunology［J］. Cell Mol Immunol, 2016, 13(3): 265-266.
［11］Sun YY, Li XF, Meng XM, et al. Macrophage phenotype in liver injury and repair［J］. Scand J Immunol, 2017, 85(3): 166-174.
［12］Wynn TA, Chawla A, Pollard JW. Macrophage biology in development, homeostasis and disease［J］. Nature, 2013, 496(7446): 445-455.
［13］Cassado ADA, Lima MRDI, Bortoluci KR. Revisiting mouse peritoneal macrophages: Heterogeneity, development, and function［J］. Front Immunol, 2015, 6: 225.
［14］Wijesundera KK, Izawa T, Tennakoon AH, et al. M1- and M2-macrophage polarization in rat liver cirrhosis induced by thioacetamide (TAA), focusing on Iba1 and galectin-3［J］. Exp Mol Pathol, 2014, 96(3): 382-392.
［15］Zigmond E, Samia-Grinberg S, Pasmanik-Chor M, et al. Infiltrating monocyte-derived macrophages and resident kupffer cells display different ontogeny and functions in acute liver injury［J］. J Immunol, 2014, 193(1): 344-353.
［16］宛硕, 黄艳, 陈庭金, 等. 巨噬细胞极化的研究进展［J］. 中国病原生物学杂志, 2015, 10(11): 1051-1054.
［17］Dixon LJ, Barnes M, Tang H, et al. Kupffer cells in the liver［J］. Compr Physiol, 2013, 3(2): 785-797.
［18］Nguyen-Lefebvre AT, Horuzsko A. Kupffer cell metabolism and function［J］. J Enzymol Metab, 2015, 1(1): 101.
［19］Sica A, Mantovani A. Macrophage plasticity and polarization: in vivo veritas［J］. J Pathol, 2012, 229(2): 176-185.
［20］Shuang W, Meng XM, Ng YY, et al. TGF-β/Smad3 signalling regulates the transition of bone marrowderived macrophages into myofibroblasts during tissue fibrosis［J］. Oncotarget, 2016, 7(8): 8809-8822.
［21］Stables MJ, Shah S, Camon EB, et al. Transcriptomic analyses of murine resolution-phase macrophages［J］. Blood, 2011, 118(26): e192-e208.
［22］Ramachandran P, Pellicoro A, Vernon MA, et al. Differential Ly-6C expression identifies the recruited macrophage phenotype, which orchestrates the regression of murine liver fibrosis［J］. Proc Natl Acad Sci U S A, 2012, 109(46): 3186-3195.
［23］Leung TM, Nieto N. CYP2E1 and oxidant stress in alcoholic and non-alcoholic fatty liver disease［J］. J Hepatol, 2013, 58(2): 395-398.
［24］Mandrekar P, Ambade A, Lim A, et al. An essential role for monocyte chemoattractant protein-1 in alcoholic liver injury: regulation of proinflammatory cytokines and hepatic steatosis in mice［J］. Hepatology, 2011, 54(6): 2185-2197.
［25］Wang M, You Q, Lor K, et al. Chronic alcohol ingestion modulates hepatic macrophage populations and functions in mice［J］. J Leukoc Biol, 2014, 96(4): 657-665.
［26］Zhao YY, Yang R, Xiao M, et al. Kupffer cells activation promoted binge drinking-induced fatty liver by activating lipolysis in white adipose tissues［J］. Toxicology, 2017, 390: 53-60.
［27］Lee J, French B, Morgan T, et al. The liver is populated by a broad spectrum of markers for macrophages. In alcoholic hepatitis the macrophages are M1 and M2［J］. Exp Mol Pathol, 2014, 96(1): 118-125.
［28］李丽萍, 邢欣, 王鹿, 等. 肝巨噬细胞在乙醇性脂肪肝发病过程中的作用研究进展［J］. 中国临床药理学杂志, 2017, 33(21): 2202-2205.
［29］娜日苏, 包纳日斯. 非酒精性脂肪肝的发病机制与流行病学的研究进展［J］. 中国医药指南, 2016, 14(3): 39-40.
［30］张云静, 宓余强. 非酒精性脂肪肝与肠道微生态的关系［J］. 肝脏, 2013, 18(5): 344-345.
［31］Reid DT, Reyes JL, McDonald BA, et al. Kupffer cells undergo fundamental changes during the development of experimental NASH and are critical in initiating liver damage and inflammation［J］. PLoS One, 2016, 11(7): e0159524.
［32］Luo W, Xu Q, Qi W, et al. Effect of modulation of PPAR-γ activity on Kupffer cells M1/M2 polarization in the development of non-alcoholic fatty liver disease［J］. Sci Rep, 2017, 7: 44612.
［33］王昭月, 卞兆连, 方一, 等. CCR2在非酒精性脂肪性肝炎中的表达及意义［J］. 肝脏, 2015, 20(5): 376-380.
［34］庄辉. 病毒性肝炎流行病学研究进展［J］. 中国继续医学教育, 2010, 2(3): 1-5.
［35］Chayama K, Hayes CN, Hiraga N, et al. Animal model for study of human hepatitis viruses［J］. J Gastroenterol Hepatol, 2011, 26(1): 13-18.
［36］Fangchao Y, Wenfeng Z, Di M, et al. Kupffer cell in the immune activation and tolerance toward HBV/HCV infection［J］. Adv Clin Exp Med, 2017, 26(4): 739-745.
［37］Gadd VL, Melino M, Roy S, et al. Portal, but not lobular, macrophages express matrix metalloproteinase-9: association with the ductular reaction and fibrosis in chronic hepatitis C［J］. Liver International, 2013, 33(4): 569-579.
［38］邢欣, 李丽萍, 王鹿, 等. 丙型病毒性肝炎中肝脏巨噬细胞的变化及作用［J］. 中国临床药理学与治疗学, 2017, 22(9): 1072-1076.
［39］Bility MT, Nio K, Li F, et al. Chronic hepatitis C infection-induced liver fibrogenesis is associated with M2 macrophage activation［J］. Sci Rep, 2016, 6: 39520.
［40］Ohtsuki T, Kimura K, Tokunaga Y, et al. M2 Macrophages play critical roles in progression of inflammatory liver disease in hepatitis C virus transgenic mice［J］. J Virol, 2016, 90(1): 300-307.
［41］Shrivastava S, Mukherjee A, Ray R, et al. Hepatitis C virus induces interleukin-1 beta (IL-1 beta)/IL-18 in circulatory and resident liver macrophages［J］. J Virol, 2013, 87(22): 12284-12290.
［42］Campana L, Iredale JP. Regression of liver fibrosis［J］. Semin Liver Dis, 2017, 37(1): 1.
［43］Wang Y, Shen RW, Han B, et al. Notch signaling mediated by TGF-β/Smad pathway in concanavalin A-induced liver fibrosis in rats［J］.World J Gastroenterol, 2017, 23(13): 2330-2336.
［44］Koyama Y, Brenner DA. Liver inflammation and fibrosis［J］. J Clin Invest, 2017, 127(1): 55-64.
［45］Locatelli L, Cadamuro M, Spirli C, et al. Macrophage recruitment by fibrocystin-defective biliary epithelial cells promotes portal fibrosis in congenital hepatic fibrosis［J］. Hepatology, 2016, 63(3): 965-982.
［46］Braga TT, Agudelo JSH, Camara NOS. Macrophages during the fibrotic process: M2 as friend and foe［J］. Front Immunol, 2015, 6: 602.
［47］Clichici S, Olteanu D, Nagy AL, et al. Silymarin inhibits the progression of fibrosis in the early stages of liver injury in CCl4-treated rats［J］. J Med Food, 2015, 18(3): 290-298.
［48］Craig AJ, Labgaa I, Villacorta-Martin C, et al. Tumor heterogeneity and resistance to targeted therapies in hepatocellular carcinoma［M］//Resistance to molecular therapies for hepatocellular carcinoma. Springer, Cham, 2017: 1-24.
［49］Downey CM, Aghaei M, Schwendener RA, et al. DMXAA causes tumor site-specific vascular disruption in murine non-small cell lung cancer, and like the endogenous non-canonical cyclic dinucleotide STING agonist, 2'3'-cGAMP, induces M2 macrophage repolarization［J］. PLoS One, 2014, 9(6): e99988.
［50］Ringelhan M, Pfister D, O'Connor T, et al. The immunology of hepatocellular carcinoma［J］. Nat Immunol, 2018: 1.
［51］陈伟, 周赟, 龚建平. 肿瘤相关巨噬细胞在原发性肝癌发生发展中的作用［J］. 临床肝胆病杂志, 2016, 32(7): 1422-1424.
［52］Wan S, Kuo N, Kryczek I, et al. Myeloid cells in hepatocellular carcinoma［J］. Hepatology, 2015, 62(4): 1304-1312.
［53］Schrammen PL, Bartneck M, Mockel D, et al. CCL2-dependent monocyte recruitment contributes to a tumor-promoting microenvironment in a combined fibrosis-HCC model［J］. J Hepatol, 2017, 66(1): S633.
［54］Krenkel O, Puengel T, Govaere O, et al. Therapeutic inhibition of inflammatory monocyte recruitment reduces steatohepatitis and liver fibrosis［J］. Hepatology, 2018, 67(4): 1270-1283.
［55］Aoyama T, Inokuchi S, Brenner DA, et al. CX3CL1-CX3CR1 interaction prevents carbon tetrachloride-induced liver inflammation and fibrosis in mice［J］. Hepatology, 2010, 52(4): 1390-1400.
［56］Huang W, Metlakunta A, Dedousis N, et al. Depletion of liver Kupffer cells prevents the development of diet-induced hepatic steatosis and insulin resistance［J］. Diabetes, 2010, 59(2): 347-357.
［57］艾雄飞, 杜丹玉, 孙立, 等. 靶向肿瘤相关巨噬细胞的治疗进展及风险［J］. 中国临床药理学与治疗学, 2016, 21(6): 697-702.
［58］Dapito DH, Mencin A, Gwak GY, et al. Promotion of hepatocellular carcinoma by the intestinal microbiota and TLR4［J］. Cancer Cell, 2012, 21(4): 504-516.
［59］Krenkel O, Tacke F. Liver macrophages in tissue homeostasis and disease［J］. Nat Rev Immunol, 2017, 17(5): 306-321.
［60］Loomba R, Lawitz E, Mantry PS, et al. GS-4997, an inhibitor of apoptosis signal-regulating kinase (ASK1), alone or in combination with simtuzumab for the treatment of nonalcoholic steatohepatitis (NASH): A randomized, phase 2 trial［J］. Hepatology, 2016, 64(6): 1119A-1120A.
［61］李校天, 尹燕, 郭永泽, 等. 1,25(OH)-2D-3干预IL-17及巨噬细胞炎性蛋白3α表达抑制大鼠肝纤维化形成的作用机制［J］. 临床肝胆病杂志, 2016, 32(12): 2331-2336.
［62］Negash AA, Ramos HJ, Crochet N, et al. IL-1 beta production through the NLRP3 inflammasome by hepatic macrophages links hepatitis C virus infection with liver inflammation and disease［J］. PLoS Pathog, 2013, 9(4): e1003330
［63］Ni YH, Fen ZG, Nagashimada M, et al. Novel action of carotenoids on non-alcoholic fatty liver disease: Macrophage polarization and liver homeostasis［J］. Nutrients, 2016, 8(7): 391.
［64］谢晓, 陆伦根. 非酒精性脂肪性肝病的潜在新疗法［J］. 临床肝胆病杂志, 2017, 33(12): 2439-2443.
［65］Farooque A, Afrin F, Adhikari JS, et al. Polarization of macrophages towards M1 phenotype by a combination of 2-deoxy-d-glucose and radiation: Implications for tumor therapy［J］. Immunobiology, 2015, 221(2): 269-281.
［66］Livingstone C. Successful Chinese German vollaborations in historical dresden［J］. Eur J Immunol, 2017, 47(3): 428-431.
［67］Rmh R, Coffelt SB, Neale TA, et al. PyMT-Maclow: A novel, inducible, murine model for determining the role of CD68 positive cells in breast tumor development［J］. PLoS One, 2017, 12(12): e0188591.
［68］Nguyen AL, Cao H, Thinn MM. Metastatic hepatocellular carcinoma treated with zoledronic acid［J］. J Oncol Pract, 2017, JOP.2017.023770.

[1]	何李华, 朱秀之, 江一舟. 三阴性乳腺癌免疫治疗研究进展[J]. 中国临床药理学与治疗学, 2023, 28(8): 842-853.
[2]	侯琼, 刘飞, 陈传荣. 免疫治疗联合抗血管生成药物+化疗在驱动基因阴性晚期非小细胞肺癌中的应用[J]. 中国临床药理学与治疗学, 2023, 28(7): 775-779.
[3]	乔红亮, 丁宁, 邓凯红, 刘彬彬, 董传江, 陈晓波, 邹黎黎. 耐甲氧西林金黄色葡萄球菌感染新型控制策略研究新进展[J]. 中国临床药理学与治疗学, 2023, 28(6): 676-687.
[4]	李阳, 潘维忠, 张晓录, 于翠翠. 回收式自体血回输对行剖宫产术患者免疫功能及炎症反应的影响[J]. 中国临床药理学与治疗学, 2023, 28(5): 514-524.
[5]	王丹, 鄢晓丽, 张渊. 幽门螺杆菌感染影响胃癌免疫治疗的研究进展[J]. 中国临床药理学与治疗学, 2023, 28(2): 228-234.
[6]	杜文鹏, 敖检根, 陶祎, 吴观胜, 何佳珂. 自身免疫疾病患者他克莫司稳态血药浓度影响因素的研究[J]. 中国临床药理学与治疗学, 2022, 27(6): 645-651.
[7]	邢博民, 郭娜, 宁海慧, 丁新耘, 马玉清. Rho激酶抑制剂对脓毒症肝损伤的影响[J]. 中国临床药理学与治疗学, 2022, 27(5): 544-550.
[8]	孟时, 王中群. 人类免疫缺陷病毒相关性肺动脉高压研究进展[J]. 中国临床药理学与治疗学, 2022, 27(12): 1431-1440.
[9]	邓颖, 白殊同. 金圣草黄素相关药理作用机制的研究进展 [J]. 中国临床药理学与治疗学, 2022, 27(10): 1155-1162.
[10]	刘乐, 齐文博, 白玉萍, 刘乾, 尹振宇, 李晓梅, 俞阳, 陈昊. 胃癌PD-1/PD-L1免疫检查点抑制剂免疫治疗影响因素分析[J]. 中国临床药理学与治疗学, 2022, 27(1): 95-101.
[11]	李玮, 胡佳丽, 王凯, 贺毅憬. 黑色素瘤免疫治疗的研究现状与展望[J]. 中国临床药理学与治疗学, 2021, 26(9): 1053-1064.
[12]	彭静, 宋静, 栾家杰. 新型冠状病毒肺炎治疗新策略：间充质干细胞疗法[J]. 中国临床药理学与治疗学, 2021, 26(9): 1073-1079.
[13]	刘文静, 武之涛, 潘国宇. 肝毒性风险的体外早期发现和预测[J]. 中国临床药理学与治疗学, 2021, 26(8): 923-930.
[14]	车津晶, 李娜. 生物类似药临床免疫原性相似性评价生物分析方法的一般考虑[J]. 中国临床药理学与治疗学, 2021, 26(7): 721-728.
[15]	章权, 石仕元, 韩贵和. 1,25二羟维生素D3在脊柱结核治疗中的免疫调节作用[J]. 中国临床药理学与治疗学, 2021, 26(7): 787-793.

肝脏巨噬细胞及其在肝损伤和修复中的作用

Hepatic macrophages in liver injury and repair

PDF (PC)

可视化

摘要/Abstract

引用本文

使用本文

参考文献

相关文章 15

编辑推荐

Metrics

本文评价